An honest, complete picture of what is happening, where things stand, and the road through the year ahead.
This document is for family who want to understand what is happening with Gerrard's health. It is honest and complete. It does not soften the findings, and it does not catastrophise. Where things are uncertain, we say so clearly.
The information here is drawn from seven medical reports across April and May 2026, plus the treatment plan from Gerrard's new haematologist, with professional medical interpretation assistance.
There is now a clear, expert-led plan with a genuinely positive goal. This update has more good news in it than the previous ones.
Gerrard has a slow-growing blood cancer called Small Lymphocytic Lymphoma (SLL). It has been quietly developing for years, with a related finding first documented in his records as far back as 2018. It came to clinical attention in April 2026 when an extensive blood clot (DVT) was found in his right thigh.
The disease is systemic: present in lymph nodes across his body and in his bone marrow. The formal stage is Stage 4. That sounds alarming, and we will not pretend otherwise, but please read the Stage 4 section below before drawing conclusions. For this type of slow-growing lymphoma, Stage 4 does not mean what it means for other cancers.
Gerrard now has a clear treatment plan, led by an excellent haematologist at the Wits Donald Gordon Medical Institute. Treatment starts on 2 June 2026. The realistic goal is remission — the cancer becoming undetectable. Gerrard will be out of action for the first 3 to 4 months, with life and work resuming around October 2026.
After a difficult first experience with another haematologist, Gerrard has been seen by a new specialist at the Wits Donald Gordon Medical Institute. The experience was completely different: patient, thorough, a deep analysis of every result, and a clear plan.
| Element | Detail |
|---|---|
| Treatment | Obinutuzumab & Venetoclax — two modern, targeted cancer drugs |
| Start date | 2 June 2026 tentative, pending final results & insurance approval |
| Duration | Approximately 1 year |
| First phase | Infusions every 2–3 days for the first 2 weeks |
| Second phase | Weekly for about a month |
| Main phase | One treatment every 28 days for the rest of the year |
| ICU stay | 2–3 nights at the start, a planned safety precaution |
| Realistic goal | Remission — cancer undetectable |
SLL is a slow-growing blood cancer. It is the same underlying disease as Chronic Lymphocytic Leukaemia (CLL); the two are considered one condition presenting in different ways. CLL shows up mainly in the blood and bone marrow; SLL shows up mainly in the lymph nodes. Gerrard's disease sits on the SLL side, with extensive lymph node involvement.
SLL is a B-cell lymphoma. It originates from a white blood cell called a B-lymphocyte, which normally produces antibodies to fight infection. When these cells become cancerous, they multiply without doing their job and crowd out healthy immune cells.
No. The evidence consistently points to a slow-growing lymphoma. The cancer cells divide slowly (a marker called Ki-67 measured up to 15%, at the lower end of the scale). The pathology specifically ruled out transformation into a more aggressive lymphoma. This is an important and reassuring point: the cancer is widespread, but it is not fast.
The new haematologist has formally staged Gerrard's disease as Stage 4. The honest reason: the cancer is present in both his lymph nodes and his bone marrow, which makes it systemic. We know "Stage 4" is a frightening phrase. So here is the essential context.
For solid-tumour cancers, Stage 4 means the cancer has spread to distant organs and usually signals a serious prognosis.
For a slow-growing blood cancer like SLL, the staging works differently. Blood and bone marrow are not "distant organs" — they are the disease's natural home. The moment SLL involves the bone marrow, it is classified Stage 4 by the rules. The majority of SLL/CLL patients are Stage 4 at diagnosis for exactly this reason.
Stage 4 SLL is still very treatable. The treatment plan aims at remission. In Gerrard's case, the situation is not hopeless at all.
The slow-growing nature of the disease, the normal blood counts, and the modern treatment available all matter far more for Gerrard's outlook than the stage number alone.
The bone marrow biopsy showed 6.9% involvement by cancer cells. This is relatively limited, and it is why his blood counts remain healthy. The bone marrow is still producing normal blood. This limited involvement is genuinely good within a Stage 4 picture.
| Measure | Result | Range | Status |
|---|---|---|---|
| Haemoglobin | 14.9 g/dL | 13.8–18.8 | Normal |
| Platelets | 177 ×10⁹/L | 150–450 | Normal |
| White cells | 7.32 ×10⁹/L | 4.0–12.0 | Normal |
| Lymphocytes | 4.13 ×10⁹/L | 1.0–4.0 | Mildly raised |
| Neutrophils | 2.09 ×10⁹/L | 2.0–7.5 | Low-normal |
Iron, ferritin, and vitamin B12 were all normal. No anaemia, no nutritional deficiency.
Gerrard's treatment combines two modern, targeted drugs. This is a recognised, current, frontline treatment for SLL/CLL. It is a fixed-duration treatment — it runs for a set period of about a year rather than indefinitely.
Gerrard will spend 2 to 3 nights in ICU when treatment begins. This is a planned safety precaution — not an emergency, and not a sign anything has gone wrong.
If Gerrard responds well, the realistic goal is remission — the cancer becoming undetectable. Modern obinutuzumab and venetoclax treatment is very effective at achieving deep, lasting remission for SLL/CLL. A year from now, the genuine and realistic hope is that Gerrard is in remission and life has returned to normal.
An echocardiogram (ultrasound scan of the heart) was done on 14 April 2026. This matters because Gerrard has had previous heart bypass surgery (a CABG), and a healthy heart is important for tolerating cancer treatment safely.
Two minor findings: mild (Grade 1) diastolic dysfunction, which is common and often age-related; and a mildly enlarged main pulmonary artery with no associated pressure problem and no strain on the heart. In short, the echocardiogram confirms Gerrard's heart is in good enough shape for the treatment ahead. An important box ticked.
In April 2026, an extensive deep vein thrombosis (DVT) — a blood clot — was found in Gerrard's right thigh, along with intermittent chest pain. Cancer is one of the best-known causes of unexplained blood clots, and this DVT is very likely the lymphoma making itself known. It was this event that triggered the scans leading to the diagnosis.
In October 2025, separately, Gerrard had a lung collapse with left-sided chest pain. The April CT scan showed some residual changes in the left lung. Whether the October event connects to the lymphoma is something the medical team is aware of. The DVT is being managed alongside the cancer treatment.
Both CT scans noted a small lung nodule (4.4–6 mm). Small lung nodules are common and usually benign. There is no evidence linking it to the lymphoma. It will simply be monitored with follow-up scans.
Two pathology results are still to be released. The treatment start date of 2 June is tentative, pending these and insurance approval. They are expected to confirm and refine the plan, not change its direction.
| Pending Result | What It Covers |
|---|---|
| Genomics | Genetic features of the cancer cells, including IGHV mutation and TP53 status. Confirms the treatment choice is optimal. |
| Cytogenetics | Chromosomal analysis of the cancer cells, looking for specific changes that carry prognostic weight. |
Gerrard is now under the care of a haematologist at the Wits Donald Gordon Medical Institute, one of the leading specialist centres in the country.
Gerrard's first haematologist consultation, in early May, was not a good experience — the care and communication were not what a diagnosis like this requires. Switching was the right decision.
The new haematologist has been outstanding: patient, thorough, and produced a clear plan with a positive goal. For a year-long treatment journey, having a specialist the family trusts makes an enormous difference. This is now in very capable hands.
The haematologist has advised that Gerrard will be out of action for 3 to 4 months during the intensive phase. The realistic expectation is that life and work resume around October 2026. Gerrard fully intends to return to work, using whatever disability benefit time off is available during the treatment months.
The treatment is significant, and this is being actively managed. The family does not need to worry about this side.
SLL compromises the immune system. The cancer cells are dysfunctional B-lymphocytes that cannot produce effective antibodies. Even with a normal white cell count, Gerrard's ability to fight infection is reduced — a condition called hypogammaglobulinaemia. Treatment will, for a period, reduce his defences further. This makes infection precautions even more important over the coming months.
Please do not visit if you are unwell, even mildly. Please do not visit if you have been around someone who is sick. Once treatment starts, this becomes even more critical. A simple cold can become a hospitalisation for Gerrard. If in doubt, message first.
| Factor | Status |
|---|---|
| Diagnosis | Confirmed — Small Lymphocytic Lymphoma |
| Disease behaviour | Slow-growing · no aggressive transformation |
| Formal stage | Stage 4 — see Stage 4 section for context |
| Bone marrow involvement | Limited (6.9%) · blood healthy |
| Heart | Cleared for treatment |
| Treatment plan | Clear, modern, well-matched |
| Treatment start | 2 June 2026 (tentative) |
| Care team | Wits Donald Gordon Medical Institute |
| Funding | Medical aid, insurance & grant |
| Genomics & cytogenetics | Pending — expected to confirm the plan |
| Realistic goal | Remission within ~1 year |
| Immediate life threat | None |